Kura Oncology spins out diabetes program into new company with $50M funding and Lilly support
read at Endpoints ↗DealPositive
Kura Oncology, known for its leukemia menin inhibitor Komzifti, announced it is separating its diabetes research into a newly formed company.
The new entity will receive $50 million in financing, with support from Eli Lilly, to advance the diabetes pipeline.
The spin‑out is being led by Caspian Therapeutics president Rob Spencer and executive chair Troy Wilson, who said the partnership will accelerate development.
The move lets Kura focus on its oncology portfolio while leveraging Lilly's expertise in metabolic diseases.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Kura Oncology spins out diabetes pipeline with $50M and Lilly's help”
read at Endpoints ↗90 words · retrieved Sep 9
comments(0)
5-min edit window · permanent after that